N-乙酰基-N'-(对乙醛酰苯甲酰基)胱胺 | 73097-03-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙酰基-N'-(对乙醛酰苯甲酰基)胱胺
• 英文名称: N-Acetyl-N'-(4-glyoxylylbenzoyl)cystamine
• 英文别名: N-[2-(2-acetamidoethyldisulfanyl)ethyl]-4-oxaldehydoylbenzamide
• CAS: 73097-03-7
• 化学式: C₁₅H₁₈N₂O₄S₂
• 分子量: 354.4
• InChiKey: NWCSKZDSXIDTDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Method of detecting a polynucleotide sequence and labelled polynucleotides useful therein
  申请人：Malcolm, Alan David Blair

  公开号：EP0124221A1

  公开（公告）日：1984-11-07

  A method of detecting nucleic acid sequences is disclosed and enzyme-labelled reagents for use therein. According to the invention sample polynucleotide is first hybridised with a polynucleotide probe comprising a nucleic acid sequence complementary to that which is to be detected, and having a polynucleotide tail, preferably a single stranded poly(dA) or poiy(dT) tail. Following attachment of the probe to the sample, an enzyme-containing marker, is attached to the probe, the marker comprising a polynucleotide having a single-stranded portion, to the base groups of which is or are attached one or more enzymatically active groups, and a polynucleotide tail which can be attached to the probe by annealing or hybridisation. Preferably the marker has a single-stranded polynucleotide tail complementary to that on the probe whereby the marker can be attached to the probe by a second hybridisation step. Presence of the sequence to be detected is confirmed by testing the labelled sample for any enzyme related activity.

  本发明公开了一种检测核酸序列的方法及其使用的酶标记试剂。根据本发明，样品多核苷酸首先与多核苷酸探针杂交，探针由与待检测的核酸序列互补的核酸序列组成，具有多核苷酸尾部，最好是单链 poly(dA) 或 poiy(dT) 尾部。将探针附着在样品上后，含酶标记物会附着在探针上，标记物包括具有单链部分的多核苷酸，其碱基组上附着一个或多个酶活性基团，以及可通过退火或杂交附着在探针上的多核苷酸尾部。标记物最好具有与探针上的单链多核苷酸尾部互补的多核苷酸尾部，这样标记物就可以通过第二杂交步骤连接到探针上。通过检测标记样品是否具有与酶相关的活性来确认是否存在要检测的序列。
• Compounds that bind to human immunodeficiency virus rev response element
  申请人：The United States of America, as represented by the Secretary, Dept. of Health and Human Services

  公开号：US10464970B2

  公开（公告）日：2019-11-05

  Compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA are provided. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also provided are methods of treating or inhibiting HIV including administering one or more of the RRE binding compounds to a subject.

  本研究提供了能与 HIV RRE RNA 结合的化合物（如肽或肽模拟物）。在一些实例中，化合物抑制（例如减少）Rev 与 RRE RNA 的结合。在一些实施方案中，化合物包括两个分子，每个分子都与 RRE 中的一个 Rev 结合位点结合。在一些实例中，分子包括肽或小分子。在一些例子中，肽包括富含精氨酸的基团。RRE 结合化合物可进一步与可检测的标签或货物分子连接。还提供了治疗或抑制 HIV 的方法，包括向受试者施用一种或多种 RRE 结合化合物。
• COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICE

  公开号：US20160237121A1

  公开（公告）日：2016-08-18

  Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.
• [EN] MOLECULAR CONJUGATE TO PROMOTE HOMOLOGOUS GENETIC RECOMBINATION<br/>[FR] CONJUGUE MOLECULAIRE PROMOTEUR DE RECOMBINAISON GENETIQUE HOMOLOGUE
  申请人：RATNER PAUL L

  公开号：WO2000032815A1

  公开（公告）日：2000-06-08

  A method and composition are disclosed for transfecting eukaryotic cells using a nucleic acid segment coupled to a site-specific chromosome-binding poylpeptide. The polypeptide-nucleic acid molecular conjugate preferably includes a recombinant DNA (rDNA) sequence, and is referred to herein as a polypeptide-linked-rDNA (PLR molecule). One example of a PLR molecule comprises an rDNA segment containing (a) a nucleotide sequence from a normally functioning structural gene, and (b) a selectable marker gene coding for antibiotic resitance, coupled by means of a covalent crosslinking reagent to a site-specific chromosome-binding polypetide (such as a transcription regulating polypeptide that binds to a specfic site in chromosomal DNA). After the PLR molecule enters a cell, by means such as electroporation, biolistics, etc., the chromosome-binding polypeptide enables transport of the PLR molecule through the cytosol and into the nucleus, using a nuclear localization sequence (NLS) domain of the polypeptide, or into a mitochondrion, using a mitochondrial leader peptide sequence. Inside the nucleus or mitochondrion, the polypeptide scans the chromosomes until it binds to a specific chomosomal binding site. This places the rDNA segment of the PLR molecule near a target site (such as an abnormal gene) in the chromosome. The desired rDNA segment contained in the PLR molecule has nucleotide sequence homology with the target gene, to enable cellular recombination enzymes to replace the targeted gene sequence with the desired gene sequence.
• [EN] COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT<br/>[FR] COMPOSÉS QUI SE LIENT À L'ÉLÉMENT DE RÉPONSE REV DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：US HEALTH

  公开号：WO2015061573A1

  公开（公告）日：2015-04-30

  Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.